Annals of Nasopharynx Cancer (ANPC) is now a member of Committee on Publication Ethics (COPE)

Starting from July 2021, AME Publishing Company is formally recognized a publisher member of Committee on Publication Ethics (COPE) and over 60 AME-published journals become a member of Committee on Publication Ethics (COPE), as part of AME’s commitment to best practice in scholarly publishing. Annals of Nasopharynx Cancer (ANPC) is among the list of COPE membership.

Read More>>

Precision Radiotherapy in Nasopharyngeal Carcinoma

This special series on “Precision Radiotherapy in Nasopharyngeal Carcinoma” was guest-edited by Dr. Wai-Tong Ng, Dr. Sophie (Shao Hui) Huang and Dr. Hai-Qiang Mai. Precision radiotherapy in NPC is a fast evolving field. The collection of articles in this special issue is a snapshot of current understanding and future direction of this topic.

Read More>>

Late Complications in the Management of Nasopharyngeal Cancer

In this issue of Annals of Nasopharynx Cancer, we present articles that are intended to discuss the long-term complications of major normal organs at risks following radiotherapy for NPC. This issue also provides the late complications of chemotherapeutic agents using concurrently with radiotherapy for NPC. Additionally, we provide an article about diet and nutrition for irradiated NPC patients who suffered from late radiation induced toxicities

Read More>>

Annals of Nasopharynx Cancer—message from the Editor-in-Chief 

It is with immense pleasure that we launch the inaugural issue of Annals of Nasopharynx Cancer—a journal dedicated to the sharing of clinical and translational scientific research in nasopharynx cancer.Nasopharynx cancer is unique; and particularly relevant to the clinical and scientific community in this part of the world. Age-standardised rates of this disease in Southern and Eastern parts of Asia exceed 15 per 100,000 person years, which are at least 15-fold greater than populations from the rest of the world. The endemic form is also invariably associated with Epstein-barr virus (EBV), although the molecular processes driving subsequent tumorigenesis remain elusive. Over the years, such observations have driven the bases for several population genetics and risk-exposure studies.

Read More>>

Editor-in-Chief: Melvin Lee Kiang Chua, MBBS, FRCR, PhD

Melvin L.K. Chua is a Clinician-Scientist at the National Cancer Centre Singapore, and an Instructor with the Duke-NUS Graduate Medical School. His research is focused on discovery and translational cancer genomics, and the development of biomarker-directed clinical trials in nasopharynx and prostate cancers.Dr. Chua graduated from the Yong Loo Lin School of Medicine, National University Singapore in 2002. He obtained his Fellowship in Clinical Oncology from the Royal College of Radiologists, and his Doctorate from the University College London in 2013. He later completed post-graduate fellowships at the Mount Vernon Cancer Centre, UK, and the Princess Margaret Cancer Centre, Toronto. Of specific mention, Dr. Chua was part of the multi-member Canadian Prostate Cancer Gene Network (CPC-GENE); the lead site of the International Cancer Genomics Consortium (ICGC) for prostate cancer. The group has published in several high impact journals, including Lancet Oncology, Nature, Nature Genetics, and Nature Communications.

Read More>>

Application of the CARE Guideline as reporting standard in the Annals of Nasopharynx Cancer

The Annals of Nasopharynx Cancer welcomes case reports which are supposed to report new observations of diseases, clinical findings or novel/unique treatment outcomes relevant to practitioners in the fields of medicine.

For completeness and transparency for published case reports, the Annals of Nasopharynx Cancer will apply the CARE guidelines (1) as reporting standards for case reports starting from October 14, 2019. For any submission of case report after the date:

Read More>>